BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15589886)

  • 1. Macroprolactinemia in women presenting with hyperandrogenic symptoms: Implications for the management of polycystic ovary syndrome.
    Escobar-Morreale HF
    Fertil Steril; 2004 Dec; 82(6):1697-9. PubMed ID: 15589886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Macroprolactinemia in the differential diagnosis of hyperprolactinemia].
    Toldy E; Löcsei Z; Szabolcs I; Kneffel P; Góth M; Szöke D; Kovács LG
    Orv Hetil; 2003 Oct; 144(43):2121-7. PubMed ID: 14661444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
    Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
    Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality?].
    Robin G; Catteau-Jonard S; Young J; Dewailly D
    Gynecol Obstet Fertil; 2011 Mar; 39(3):141-5. PubMed ID: 21388855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism.
    Unluhizarci K; Kaltsas G; Kelestimur F
    Eur J Clin Invest; 2012 Jan; 42(1):86-94. PubMed ID: 21623779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polycystic ovary syndrome associated with remarkable hyperprolactinemia--case report].
    Owecki M; Sowiński J
    Pol Merkur Lekarski; 2004 Oct; 17(100):385-7. PubMed ID: 15690710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early diagnosis, presenting complaints, and management of hyperandrogenism in adolescents.
    Schroeder B
    Curr Womens Health Rep; 2001 Oct; 1(2):124-30. PubMed ID: 12112959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macroprolactinemia in childhood and adolescence: a cause of hyperprolactinemia.
    Tütüncüler F; Darendeliler F; Aygün M; Hekim N
    Turk J Pediatr; 2006; 48(2):143-7. PubMed ID: 16848115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome.
    Fraser IS; Kovacs G
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):813-23. PubMed ID: 15380149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome.
    Lowenstein EJ
    Dermatol Ther; 2006; 19(4):210-23. PubMed ID: 17004997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group.
    Farah L; Lazenby AJ; Boots LR; Azziz R
    J Reprod Med; 1999 Oct; 44(10):870-4. PubMed ID: 10554748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin secretion in polycystic ovary syndrome (PCOS).
    Szosland K; Pawlowicz P; Lewiński A
    Neuro Endocrinol Lett; 2015; 36(1):53-8. PubMed ID: 25789595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome.
    Carmina E; Azziz R
    Fertil Steril; 2006 Jul; 86 Suppl 1():S7-8. PubMed ID: 16798288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characterization of patients with macroprolactinemia and monomeric hyperprolactinemia.
    Can M; Guven B; Atmaca H; Acıkgoz S; Mungan G
    Kaohsiung J Med Sci; 2011 May; 27(5):173-6. PubMed ID: 21527183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What every physician should know about polycystic ovary syndrome.
    Rosenfield RL
    Dermatol Ther; 2008; 21(5):354-61. PubMed ID: 18844713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
    Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women.
    Alvarez-Blasco F; Botella-Carretero JI; San Millán JL; Escobar-Morreale HF
    Arch Intern Med; 2006 Oct; 166(19):2081-6. PubMed ID: 17060537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Androgenization in patients with polycystic ovary syndrome].
    Gasparov AS; Pshenichnikova TIa; Alieva EA; Fedorova TA; Vetr M
    Acta Univ Palacki Olomuc Fac Med; 1990; 126():241-6. PubMed ID: 2151091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.